Press release, Helsinki, 16 February 2026 at 11:30 AM (EET)
Nexstim Receives Clearance for its NBS 6 Diagnostics System in UAE
Nexstim Plc ("Nexstim" or "Company") has received import clearance for its NBS 6 diagnostics system in the United Arab Emirates (UAE).
The NBS 6 enables Nexstim's unique E-field navigated TMS technology to be used more easily than ever before. Part of this new product generation is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer's research or clinical interests.
All Nexstim products are based on the Company's state-of-the-art nTMS (navigated transcranial magnetic stimulation) technology. Compared to other TMS solutions, Nexstim has a strong advantage when it comes to the accurate and precise delivery of stimulation.
Nexstim released the NBS 6 diagnostics system in the European Union and the United States in October 2025.
Mikko Karvinen, CEO of Nexstim, comments: "We have had a steadily strengthening presence in the Middle East, and we are happy to be able to offer our NBS 6 diagnostics system in the UAE. Since its release, our new product has generated interest among current and potential future users in the EU and the US, and we are confident about our international expansion opportunities."
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim's Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
